Thrombosis Risk In Taxus And Cypher Is Real, TCT Data Shows; Now What?
This article was originally published in The Gray Sheet
Executive Summary
With a growing consensus coming out of last week's Transcatheter Cardiovascular Therapeutics meeting that first-generation drug-eluting stents (DES) are associated with an increased long-term risk of blood clots, cardiologists are grappling with how use of these blockbuster products might need to be modified
You may also be interested in...
Newer Drug-Eluting Stents May Put Late Thrombosis Issues To Rest – Meta-Analysis
In an analysis of about 50,000 patients in 49 different clinical studies, cobalt-chromium everolimus-eluting stents like Abbott’s Xience showed a definitive thrombosis advantage over bare-metal stents at one year and two years following the initial procedure.
Newer Drug-Eluting Stents May Leave Late Thrombosis Saga Behind – Meta-Analysis
In an analysis of about 50,000 patients in 49 different clinical studies, cobalt-chromium everolimus-eluting stents like Abbott’s Xience showed a definitive thrombosis advantage over bare-metal stents at one year and two years following the initial procedure.
NEJM Articles Fuel Debate On Drug-Eluting-Stent Safety
Results of a Swedish registry of almost 20,000 patients, published in the New England Journal of Medicine, are adding fuel to the ongoing debate on drug-eluting-stent safety